Pitch Companies & Speakers

REGISTER FOR
KEYNOTE & PITCH SESSION

B2B MEETINGS WITH JAPANESE COMPANIES

Deadline:

Tuesday, July 13, 2021

5:00 PM PDT

Please contact Japanese companies via the E-mail listed to arrange a meeting

Yoshinori "Josh" Kamiya

Nippon Life X

Head of Silicon Valley team

E-mail

Nippon Life Insurance Company

Nippon Life has collaborated with a number of startups to support their expansion into Japan since entering Silicon Valley in 2016, and in 2020, launched a CVC to start investment activities. We have $100m fund for early stage InsureTech, Healthtech and Fintech startups. Our healthcare business in Japan is branded as Wellness-star and we have started to provide services for companies and employees to support health management. Now, we are aiming to expand our business to local community and individuals. We analyze employee health and medical information to create reports, and provide various programs to help employees and local residents become healthier. It has already been adopted by 120 companies and we hold the health data of 2 million employees. Focus areas are early detection and prevention of diabetes, cancer, heart disease, brain disease, dementia, mental health　as well as health data analysis. We believe that digital health is the key to supporting people's health.

https://www.nissay.co.jp/english/

Kenta Shimoda
Manager of Innovation Strategy Unit
E-mail

Dai-ichi Life Holdings, Inc.

We offer products & services across multi-distribution channels that help protect and improve the wellbeing of all, by building strong relationships with customers, communities and diverse business partners in a rapidly changing environment.

Various initiatives are enhanced based on sustainable and ethical growth of corporate values.
• Collaborate with startups and academia, in light of digital transformation of the economy and society, to develop advanced business models stepping into the next generation.
• Pursue growth opportunities in overseas life insurance and asset management businesses

• Balance solving social challenges and creating shareholder value through ESG and responsible investments

LAB: https://www.dai-ichi-life-hd.com/en/innovation_lab/index.html

Partnership Agreement with Silicon Valley Startups: https://www.dai-ichi-life-hd.com/en/newsroom/newsrelease/2018/pdf/index_015.pdf

Yuko Nakagawa

Executive Officer and General Manager of Business Planning Dept.

E-mail

SOMPO Himawari Life Insurance Inc.

Transformation from Life Insurance Companies

In addition to the rapid aging of the population, the declining birthrate and increasing longevity of the population have led to a significant increase in medical costs, especially for the elderly. It is expected to increase further in the future. In order to solve these social issues in Japan, we provide a new value called "Insurhealth," which integrates the original function of insurance and health care, in order to keep people healthy and happy.

In order to create a world where lifestyle-related diseases, diabetes, cancer, dementia, etc. can be avoided, detected early and prevented, we collaborate with companies that have the latest technology in each country to provide our customers with "Insurhealth."

https://www.sompo-hd.com/en/group/life/ (English) https://www.himawari-life.co.jp/ (Japanese) https://twitter.com/sompo_himawari (Japanese)

DEVICE AND MATERIALS

Hideo Nawata
Senior Manager

E-mail

TEIJIN PHARMA LIMITED

Teijin Pharma focuses on two main sectors: pharmaceuticals and medical devices that enhance home based healthcare. Teijin Pharma is participating in this event to introduce our company and network with medical device/digital solution start ups that may be a fit for our strategic goals. We are particularly interested in non-invasive technologies and technologies that make it easier to treat patients at home. Historically, Teijin Pharma has had a strong portfolio of technologies and services in the respiratory and sleep areas. We are trying to enhance our existing business and expand into other chronic disease areas, like behavioral-health, lifestyle diseases, rehab, especially if these technologies allow for more effectively treatment at home. Our objective is to support the patients to enhance QOL by home healthcare.

https://www.teijin-pharma.com/

Koji Yoshida

Senior Electronic Engineer

Medical Device Development
E-mail

Masataka Ohara

Manager
Strategic Alliances Partnerships
E-mail

Murata Manufacturing Co., Ltd.

"Murata developing advancements in components and solutions for the medical devices of tomorrow"

Murata is a worldwide leader in the design, manufacture and supply of electronic components and solutions, and is well known for its expertise in advanced materials,, broad product portfolio, global manufacturing capabilities and sales channel. Murata is looking for collaborative partners towards increasing growth in the Healthcare and Medical markets in the US.

Murata’s new technologies, such as stretchable electronics and electrode materials, present opportunities to explore collaborations in numerous application areas. Murata offers it partners support in various areas, including engineering, product development, customer expansion, channels to market, brand recognition, financial support, and more.

https://www.murata.com/en-us

Keiko Sakaguchi
Manager of Robot Materials
Business Development Dept.
New Business Incubation Center

E-mail

Mitsui Chemicals, Inc.

Examples of Mitsui Chemicals Collaborative Activities

Bionic-EyE® with Tokyo University: 

Bionic-EyE® is our brand-new surgical simulator for Ophthalmologists, thanks to supervision of Dr. Hajime Aihara, a renowned ophthalmologist of Tokyo University. The high-fidelity simulator equips elastic skin and eyeballs, which are developed by fully utilizing Mitsui Chemical’s polyurethane design technologies.

Reference: Bionic-EyE® won Good Design Award in 2019 

Alliance with Elephantech: 

Together with the world’s first flexible circuit board manufacturer Elephantech Inc, Mitsui Chemicals pursues new applications of FPC P-Flex®. A new factory was built in Mitsui’s Nagoya Work for mass production of the unique flexible circuit boards. We believe that the flexible circuit board should make future wearable devices more sensible and sophisticated. 

Alliance with B9Creation:  

B9Creation is a leading 3D Printer company of the United States. Mitsui Chemicals works together to establish rapid digital workflow from patients’ data scanning to creation of artificial tooth.

Press Release: Mitsui Chemicals to Acquire Shares of US 3D Printer Manufacturer B9Creations

Daisuke Kawakami

Director

Life Innovation Dept.

Michael Nilan

Business Development Consultant

E-mail

(612) 558-0344

Toray Industries, Inc.

Toray is one of the world's leading chemical and materials companies, with sales exceeding $22 Billion and over 45,000 employed around the globe in 26 countries.

Along with Toray's core technologies of organic synthetic chemistry, polymer chemistry, and biotechnology, Toray is also a global leader in the development and application of nanotechnology. With these advanced materials technologies, Toray has been able to develop and serve the healthcare and medical markets with many innovative and new products. A few product examples are highly precise wearable ECG garments, breathable PPE, and transparent ABS Resin with superior moldability used in the medical device industry. Toray has launched a best-in-industry polymer optical fiber with the world's highest Numerical Aperture used in endoscopes, etc., as well as a game-changing ultra-fine fiber wiping cloth with superior efficacy against germs and viruses with applications in many settings.

https://www.toray.us/
https://www.linkedin.com/company/toray-industries-inc-/

DRUG DISCOVERY

Hisanori Matsui, PhD.

Neuroscience Pipeline Sustainability & Partnership

E-mail | LinkedIn

Takeda Pharmaceutical Company Limited

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company with 240 years of history. Neuroscience is a core therapeutic area for Takeda. Our focused diseases are age-related neurological disorders, hereditary neurological disorders and neuromuscular disorders. We need innovation enablers which include brain and muscle shuttle/delivery, patient segmentation and disease classification, and human-based Neuroscience research platform. From the initial idea to the launch of the medicine we are committed to working in partnership with external experts who share our vision and possess the knowledge and scientific capabilities to make truly transformative medicines for the patients we serve.

Takeda HP / LinkedIn / Twitter / YouTube

Satoshi Haneda

Team Leader

Life Science Development Center

E-mail

SEKISUI CHEMICAL CO., LTD

GLOBAL100: https://www.corporateknights.com/reports/2021-global-100/

Shinichi Miyake, Ph.D.

Senior Manager

Scouting group

E-mail

Astellas Innovation Management LLC

Astellas Innovation Management (https://aim.astellas.com/en) plays an important role in identifying, evaluating and accessing early-stage innovations into Astellas through a number of partnerships and alliances with various external partners. Located in key Bio-Hubs in the Bay Area CA, Cambridge MA, Cambridge UK, as well as Tsukuba Japan, AIM has built and developed a strong network across academia and the healthcare sectors.

AIM is focused on 3 major elements to drive innovation across Astellas

(1) biology and pathophysiology driving disease processes

(2) different and unique therapeutic modality/technology

(3) disease of high unmet medical need

Our priorities are focused on those partners who can address these elements. Greater details with regard to priorities and areas of focus for Astellas can found in the following link. (https://aim.astellas.com/en/our-focus)

Sakae Asanuma

CFA, MBA

PRESIDENT & CEO

E-mail

Takahiro Hagisako

Head of GM Office

E-mail

Shonan Health Innovation Park

Shonan Health Innovation Park (Shonan iPark) began operations in April 2018, with the aim of creating a co-location ecosystem comprised of researchers, industry experts, venture startups, government, and academia who will collaborate and co-create - to accelerate research, with the aim of transforming cutting-edge science into impactful health solutions for patients across the world.

Takeda Pharmaceutical Company launched Shonan iPark by transforming its Shonan research site to enhance scientific innovation with the aspiration to become a world-class ecosystem. Shonan iPark is supported by the local government and aligns well with the backbone of the government’s economic and revitalization strategy.

We welcome aspirational entrepreneurs and researchers to make iPark their home. Let's work together to open a new era of science, build a new success model of researcher, and create the world-leading science park!

https://www.shonan-health-innovation-park.com/en/

LinkedIn / YouTube / Twitter (global)